Pre-earnings brief
Reports
Thu, Nov 12, 2026
Est. EPS
—
Est. revenue
—
Implied move
±16.4%
EPS beat rate
13%
Scholar Rock Holding Corporation is a biotechnology company focused on developing therapies for serious diseases by targeting the growth factors that regulate cellular processes. Operating in the health care sector, its innovations are crucial for addressing unmet medical needs, particularly in rare diseases.
Last quarter
In Q2 2026, Scholar Rock reported an EPS of -$0.84, slightly missing expectations. The stock reacted positively, gaining nearly 10% the following day.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
-9.48%
Avg 1-day reaction
+2.44%
Overall, expectations for Scholar Rock's upcoming earnings are uncertain, with no analyst estimates available. Investors are particularly focused on the company's ability to manage costs and drive revenue.
Bull case
If Scholar Rock can demonstrate significant progress in its drug development pipeline, it may attract more investor interest and drive stock prices higher.
Bear case
Conversely, if the company fails to show meaningful advancements or reports higher-than-expected losses, it could lead to a negative market reaction.
The print will turn on these.
Q1
What specific advancements can Scholar Rock report regarding its drug pipeline?
Progress in drug development is crucial for investor confidence and can significantly impact stock performance.
Q2
How is the company managing its R&D expenses in light of recent financial results?
Effective cost management is essential for a biotech firm, especially in a period of high spending on research and development.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±11.1%
Why consensus could be wrong
The Street may be underestimating the potential impact of Scholar Rock's drug pipeline advancements, which could lead to unexpected positive results.
Supporting evidence
Recent stock movements suggest that investors are still optimistic about long-term growth despite recent losses.
The options market indicates a significant expected move, reflecting potential surprises that analysts may not be anticipating.
Key risk
If the company reports any positive developments in its drug pipeline, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for breakthrough therapies against the backdrop of ongoing financial losses.
Bull confirmed if
Demonstrating a clear path to regulatory approval for one of its leading candidates would confirm the bull case.
Bear confirmed if
Reporting a larger-than-expected loss without a clear plan for improvement would confirm the bear case.
What the market is pricing for the move.
Implied Move
±10.87%
Historical Avg
±6.6%
The options market is pricing in a significant move, suggesting that traders expect volatility surrounding the earnings report.
Options are pricing ±16.4% while SRRK has averaged ±6.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
47.2%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 30 (43%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 30 faded and 17 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.3%, with a raw directional average of +1.7% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Scholar Rock beats expectations, history suggests the stock could rise by around 2.92%, confirming a positive outlook.
In line / cautious
An in-line report with cautious commentary may lead to a muted response, reflecting uncertainty in future growth.
Miss
If the company misses expectations, history suggests a potential decline of around 2.92%, indicating investor disappointment.
The lines on the call that would change the story.